YEŞİM ŞERİFE BAYRAKTAR, İPEK DUMAN, ATEŞ DUMAN

Geriatrik ve non-geriatrik yoğun bakım hastalarında kolistin ilişkili nefrotoksisite: Retrospektif kohort çalışması

Amaç: Kolistin (kolistimetat sodyum) son yıllarda çoklu ilaç direnci gösteren gram negatif bakterilerin oluşturduğu nozokomiyal enfeksiyonların tedavisinde kullanılmaktadır. Kolistin kullanımı sonucu gelişen ciddi advers etkiler arasında nefrotoksisite önemli bir yer tutar. Geriatrik hastalarda kolistin ve nefrotoksisite ilişkisine yönelik çalışmalar kısıtlıdır. Amacımız Yoğun Bakım Ünitesinde Acinetobacter baumannii enfeksiyonu nedeniyle kolistin tedavisi alan geriatrik (≥65 yaş) ve nongeriatrik (

Objective: In recent years colistin (colistimethat sodium) is used to treat nosocomial infections caused by Gram-negative bacteria showing multi-drug resistance. Nephrotoxicity is an important adverse effect resulting from the use of colistin. Studies on colistine and nephrotoxicity in geriatric patients are limited. Our aim was to evaluate the development of acute renal failure (ARF) and demographic data in terms of laboratory and clinical parameters in geriatric (≥65 years) and nongeriatric (

PDF

___

El-Demiry MI, Smith G, Ritchie AW, et al. Local immune responses after intravesical BCG treatment of carcinoma in situ. Br J Urol 1987; 60: 543-8.
Böhle A, Gerdes J, Ulmer AJ, et al. Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990; 144: 53-8.
Lamm DL. Efficacy and safety of bacillus Calmette±Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000; 31: 86-90.
Leebeek FW, Ouwendijk RJ, Kolk AH, Dees A, Meek JC, Nienhuis JE, et al. Granulomatous hepatitis caused by Bacillus Calmette-Guérin (BCG) infection after BCG bladder instillation. Gut 1996; 38: 616-8.
Gonzalez OY, Musher DM, Brar I, Furgeson S, Boktour MR, Septimus EJ, et al. Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003; 36: 140-8.
Soylu A, Ince AT, Polat H, Yasar N, Ciltas A, Ozkara S, et al. Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with bacillus Calmette-Guérin. Ann Clin Microbiol Antimicrob 2009; 8: 12.
Ersoy O, Aran R, Aydinli M, Yonem O, Harmanci O, Akdogan B, et al. Granulomatous hepatitis after intravesical BCG treatment for bladder cancer. Indian J Gastroenterol 2006; 25: 258-9.
Lamm DL. Complications of Bacillus Calmette–Guérin immunotherapy. Urol Clin North Am 1992;19:565-72.
Rival G, Garot D, Mercier E, et al. Acute respiratory failure and septic shock induced by Mycobacterium bovis. A rare side effect of intravesical BCG therapy. Presse Med 2006;35:980.
Alzeer AH, FitzGerald JM. Corticosteroids and tuberculosis: risks and use as adjunct therapy. Tuberc Lung Dis 1993; 74:6-11.
Dooley DP, Carperter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin Infect Dis 1997; 25:872-87.
Grange JM. Complications of bacille Calmette–Guérin (BCG) vaccination and immunotherapy and their management. Commun Dis Public Health 1998;1:84–8.
Nadasy KA, Patel RS, Emmett M, et al. Four cases of disseminated Mycobacterium bovis infection following intravesical BCG instillation for treatment of bladder carcinoma. South Med J 2008;101:91-5.
Soylu A, Ince AT, Polat H, et al. Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with bacillus Calmette-Guérin. Ann Clin Microbiol Antimicrob 2009; 8: 12.
Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
Paterson DL, Patel A. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: Review of complications and their treatment. Aust NZJ Surg 1998; 68: 340-4.
Steg A, Adjiman S, Debre B. BCG therapy in superficial bladder tumours- complications and precautions. Eur Urol 1992; 21: 35-40.
Martinez-Piñeiro JA, Flores N, Isorna S, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of Intravesical bacilli Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002; 89: 671-80.
Koga H, Kuroda M, Kudo S, et al. Adverse drug reactions of intravesical bacillus Calmette-Guérin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder. Int J Urol 2005; 12: 145-51.
Irie A, Uchida T, Yamashita H, et al. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence. Int J Urol 2003; 10: 183-9.
Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG. Complications of bacillus Calmette-Guérin immunotherapy in 1278 patients with bladder cancer. J Urol 1986; 135: 272-4.